CureMD to Integrate Tempus' Advanced Genomic Testing Capabilities Into EHR System

CureMD, a leading provider of comprehensive technology solutions for community oncology, is proud to announce its partnership with Tempus, a leader in artificial intelligence and precision medicine, to integrate Tempus' advanced genomic testing capabilities into CureMD's cutting-edge Electronic Health Record (EHR) system.

We are excited to join forces with Tempus to integrate their genomic testing capabilities into our EHR system. This partnership represents a significant milestone in our commitment to deliver the most cutting-edge solutions to our healthcare providers, ensuring they have the most advanced precision medicine tools at their disposal to provide exceptional patient care."

Wasif Toor, VP of Oncology, CureMD

The integration of Tempus' genomic testing into CureMD's ecosystem will empower healthcare providers to place genomic testing orders directly in the EHR at the point of care, allowing physicians to streamline their workflows and provide more genomic testing opportunities for patients.

This is the first step in a multi-year partnership to provide physicians with the in-workflow tools that will positively impact a patient with cancer's early detection, treatment, and survival. The evolving collaboration will make discrete, structured genomic testing results available at the point of care in the EHR for timely treatment decisions, prognosis, and risk.

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Single-Cell Sequencing Sheds Light on Breast Cancer Genetics